Press Releases

 
Press Releases
  Date Title and Summary View
May 19, 2015
NEW YORK and PARIS, May 19, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that Adam Zlotnick, PhD, Assembly's Chief Scientific Advisor and Chair of its HBV & Virology Science Advisory Board, discussed the science underlying the company's Core Protein Allosteric Modifiers (CpAMs) at the Second ANRS HBV Cure Worksh...
Mar 19, 2015
NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly") announced today the pricing of an underwritten public offering of $75 million, or 5,555,555 shares of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a pub...
Mar 18, 2015
NEW YORK, March 18, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly") announced today that it is commencing an underwritten public offering of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission. All of the shares in the offering ar...
Feb 20, 2015
NEW YORK, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in the 2015 RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York City. Assembly's Chief Executive Officer Derek Small and Chief Medical Officer Uri Lopatin will present on February 25, 2015 at 4...
Feb 17, 2015
NEW YORK, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced a number of senior management changes. Derek Small has been named Chief Executive Officer, in addition to his current position as President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Ch...
Dec 3, 2014
NEW YORK, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in two investor conferences this week. The company has been invited to join a Hepatitis B Virus panel at the 26th Annual Piper Jaffray Healthcare Conference being held at The New York Palace in New York City. The panel is sch...
Oct 1, 2014
NEW YORK, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Assembly) (Nasdaq:ASMB) announced today that on October 1, 2014, it entered into an agreement with institutional investors for the sale of 1,959,000 shares of its common stock at the price of $8.04 per share, resulting in $15.75 million in gross proceeds to the company. The sale...
Jul 25, 2014
NEW YORK, July 25, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB), a biopharmaceutical company developing innovative treatments for hepatitis B virus (HBV) and C. difficile-associated diarrhea (CDAD,) today announced that it will not pursue further development of VEN 307, an investigational product for the treatment of anal fissu...
Jul 14, 2014
NEW YORK, July 14, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that its stockholders have approved the issuance of common stock in connection with the merger between Ventrus and Assembly Pharmaceuticals, Inc. in an all-stock transaction. The merger was effective at 5:00 p.m. ET on July 11, 2014.  Ventrus...
Jun 9, 2014
NEW YORK, June 9, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) ("Ventrus" or the "Company") today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) in connection with the upcoming annual meeting of Ventrus stockholders.   The Company also announced that it is commencing the ...
Page:
1
NextLast
= add release to Briefcase

Investor Data

© 2015 Assembly Biosciences

Back to top